blood coagulation


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

coagulation

 [ko-ag″u-la´shun]
1. in surgery, the disruption of tissue by physical means to form an amorphous residuum, as in electrocoagulation or hotocoagulation.
2. in colloid chemistry, solidification of a sol into a gelatinous mass.
blood coagulation clotting.
diffuse intravascular coagulation (disseminated intravascular coagulation (DIC)) see disseminated intravascular coagulation.
coagulation factors factors essential to normal blood clotting, whose absence, diminution, or excess may lead to abnormality of the clotting. Twelve factors, commonly designated by Roman numerals, have been described (I–V and VII–XIII; VI is no longer considered to have a clotting function). (See table 6.)

Factor I is a high-molecular-weight plasma protein that is converted to fibrin through the action of thrombin; deficiency conditions are called afibrinogenemia and hypofibrinogenemia. Called also fibrinogen. Factor II is a glycoprotein present in the plasma that is converted into thrombin in the common pathway of coagulation; deficiency is called hypoprothrombinemia. Called also prothrombin. Factor III is involved in the extrinsic pathway of coagulation, activating factor X; called also tissue thromboplastin or factor.

Factor IV is calcium, required in many stages of blood clotting. Factor V is a heat- and storage-labile material, present in plasma and not in serum and is involved in the intrinsic and extrinsic pathways of coagulation, causing the cleavage of prothrombin to the active thrombin. Deficiency causes parahemophilia. Called also accelerator globulin or factor and proaccelerin. Factor VI is no longer considered in the scheme of hemostasis, and hence is assigned neither a name nor a function.

Factor VII is a heat- and storage-stable material, present in serum and in plasma and participating in the extrinsic pathway of coagulation, acting with factor III to activate factor X. Deficiency, either hereditary or acquired (vitamin k deficiency), leads to hemorrhagic tendency. Called also proconvertin and serum prothrombin conversion accelerator (SPCA). Factor VIII is a relatively storage-labile material that participates in the intrinsic pathway of coagulation, acting as a cofactor in the activation of factor X. Deficiency, an X-linked recessive trait, results in hemophilia a (classical hemophilia). Called also antihemophilic factor (AHF) and antihemophilic globulin (AHG). Factor IX is a relatively storage-stable substance involved in the intrinsic pathway of coagulation, acting to activate factor X. Deficiency of this factor results in a hemorrhagic syndrome called hemophilia b (or Christmas disease), which is similar to classical hemophilia A. It is treated with purified preparations of the factor, derived from human plasma or recombinant, or with factor IX complex. Called also plasma thromboplastin component (PTC) and antihemophilic factor B.

Factor X is a heat-labile material with some storage stability, which is involved in both intrinsic and extrinsic pathways of coagulation, uniting them to begin the common pathway. Once activated, it complexes with calcium, phospholipid, and activated factor V to form prothrombinase, which cleaves and activates prothrombin to thrombin. Called also Stuart or Stuart-Prower factor. Factor XI is a stable factor involved in the intrinsic pathway of coagulation, activating factor IX. Deficiency results in hemophilia c. Called also plasma thromboplastin antecedent (PTA) and antihemophilic factor C. Factor XII is a stable factor activated by contact with glass or other foreign substances, which initiates coagulation through the intrinsic pathway by activating factor XI; called also Hageman factor. Factor XIII is a factor that polymerizes fibrin monomers, enabling fibrin to form a firm blood clot. Deficiency causes a clinical hemorrhagic diathesis. Called also fibrin-stabilizing factor.

blood coagulation

a nursing outcome from the Nursing Outcomes Classification (NOC) defined as the extent to which blood clots within a normal period of time. See also Nursing Outcomes Classification.

blood clot·ting

(blŭd kloting)
Process in which platelets, in conjunction with clotting factors, transform blood from a liquid into a semisolid mass.
Synonym(s): blood coagulation.

blood coagulation

the process of clotting, which is one of the body's natural means of stopping bleeding (haemostasis), activated by damage to the vessel lining. Results from a complex cascade reaction, dependent on the presence of ionized calcium and involving many 'clotting factors', some always present in the blood and some released from damaged tissue and platelets. The endproduct is a mesh of fibrin in which blood cells are trapped to form a solid mass. See also anticoagulant.
References in periodicals archive ?
Coverage of the Blood coagulation pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Blood coagulation.
to commercialize patented technologies for monitoring blood coagulation.
Frequent blood coagulation testing is known to improve therapeutic outcomes for mechanical heart valve patients who take oral anticoagulation medications.
The site contains easy-to-understand clinical and technical information about HemoSense's INRatio blood coagulation monitoring system, and also provides references to scientific journals regarding new developments in coagulation monitoring as well as background information about the company and press releases from the past year.
president and chief technology officer, to commercialize his patent-pending technologies for monitoring blood coagulation.
With the completion of this collaboration agreement, TKT has enhanced its position as a strong player in the development and commercialization of gene therapy products for blood coagulation disorders.
OB - OTC BB; HDO - BSX), a New Jersey biotech company, has developed an anti-thrombogenic polymer coating complex (F202) that minimizes blood coagulation.
We are delighted to have been selected by CheckUps as the supplier of blood coagulation monitoring equipment for their new Wal-Mart-based clinics," said Jim Merselis, President and CEO of HemoSense.
His experience and knowledge of the industry will be instrumental in developing and carrying out our strategy to increase point-of-care and home testing of blood coagulation levels with our INRatio(R) system.